In The Burrill Report you will find how life science companies are faring with their cash positions, whether or not the IPO market is returning and what companies are doing about it; how emerging technology promises to revolutionize vaccines, and what’s happening in the realm of new antibiotics.

Our regular features include:

• Venture financings
• Public Financings
• Grants
• Partnering and licensing deals
• Mergers and acquisitions
• Nasdaq non-compliance notices and regained compliance
• FDA new product approvals
• Upcoming PDFUA dates
• Layoffs and hirings
• Executive changes
• Bankruptcies and liquidations
• Legal news
• Patent news
• Research news

And a rundown on the Burrill family of life science indices.

 Order now